SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced Kerry Ingalls has joined the company as Chief…
Read More
SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today announced the United States…
Read More
MIAMI, April 22, 2019 /PRNewswire/ -- Rapha Capital Management, LLC (https://www.raphacap.com), an investment management firm located in Miami, Florida, and their associated entities announced today their participation in a Series C financing for…
Read More
The race to bring CAR-T cell therapy to multiple myeloma, a persistent and deadly cancer of the bone marrow, continued on Monday with a fresh round of funding for Poseida Therapeutics. Swiss…
Read More
Poseida Therapeutics, Inc. Poseida Therapeutics Announces Notice of Allowance for New Patents and Registration of New Trademarks Key Patent Covers Manufacture of Therapeutic Products Containing a High Percentage of T…
Read More
Is there enough enthusiasm among biotech investors to push through a $115 million-plus IPO on the latest biotech staking out their claim with a new-and-improved BCMA CAR-T therapy? Poseida Therapeutics…
Read More
SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging proprietary non-viral gene engineering technologies to create life-saving therapeutics, today provided an update on…
Read More
The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate, the Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of relapsed or refractory multiple myeloma. Preliminary…
Read More
Drugs which target the BCMA receptor look set to feature prominently at this year’s American Society of Haematology (ASH) meeting, with new trial results expected for several of the leading…
Read More
Efficacy and safety continue to be a major advantage, with a very high response rate, no dose limiting toxicities and only a single incidence of suspected cytokine release syndrome P-BCMA-101…
Read More
SAN DIEGO, July 20, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene engineering technologies into lifesaving cell therapies, today announced that the…
Read More
San Diego’s Poseida Therapeutics has raised $30.5 million in venture capital funding, the cancer therapy developer said Tuesday. The Series B financing round was led by new investor Longitude Capital, along…
Read More